Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at Sanford C Bernstein Operational Decisions Conference Transcript

Nov 04, 2021 / 04:30PM GMT
Release Date Price: R$50.68 (+2.97%)
Aaron Gal;Mark A. Mintun
Sanford C. Bernstein & Co., LLC., Research Division - Senior Research Analyst;Eli Lilly and Company - Vice-President of Pain & Neurodegeneration Research & Clinical Development<

Hi, everybody, and thank you for joining us today. This being the Operational Decisions Conference, we are trying to get to some deep topics, not cover everything but cover a few deep topics. And Lilly's been kind enough to share with us today not 1 but more of the 3 kind of like senior managers with specific topical responsibilities.

So we're going to have to go over the next 45 minutes relatively quickly through discussion with those 3 experts. We have Mark Mintun, which is the Head of R&D in Neurology and Pain and the President of Avid Radiopharm, so he's the man on everything Alzheimer's. We have Jake Van Naarden, who is responsible for Oncology, I guess soups-to-nuts, all the way from R&D to commercial business; and Jamie Croaning, which is responsible for the tirzepatide program. Thank you very much for all 3 of you for joining us today.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot